Tushi Singh MD, Arunee Motes MD, Myrian Vinan-Vega MD, Kenneth Nugent MD
Pulmonary arterial hypertension (PAH) is an important health issue in the twenty-first century. The introduction of highly active retroviral therapy has prolonged survival in patients infected with the human immunodeficiency virus (HIV), and this has led to the emergence of new health issues, including PAH, in those patients. This review considers the advances in understanding the pathophysiology of PAH in HIV infections and the approaches to the treatment of these patients.
Keywords: Pulmonary arterial hypertension, HIV, pathophysiology, treatment
Article citation: Singh T, Motes A, Vinan-Vega M, Nugent K. Pulmonary arterial hypertension in human immunodeficiency virus infections. The Southwest Respiratory and Critical Care Chronicles 2024;12(53): 12–18
From: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas
Submitted: 9/22/2024
Accepted: 10/12/2024
Conflicts of interest: none
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.